case 23: health behaviours, diabetes and endocrine disease Flashcards
by which organ and cells is insulin produced
beta cells in the islets of langerhans of the pancreas
what is C peptide
is by-product of insulin production and is used as a measure of endogenous insulin
which process does glucagon inhibit
glycolysis
process of thyroid hormone being released
hypothalamus realises TRH which stimulates pituitary
pituitary releases TSH which stimulates the thyroid
thyroid releases T3 and T4
Qs for itchy penis
pain
discharge
dysuria
itching/burning
sexual history
testicular swelling
lymph node swelling in groins
history of trauma/previous surgery
proper name for penis thrush
candidal balanitis
rfs for candidal balanitis
diabetes mellitus
oral abx
poor hygiene
immunosuppression
normal blood sugar levels
4-7mmol before meals
less than 9mmol 2hrs after meals
glucose criteria for diagnosing diabetes
in symptomatic:
fasting glucose greater than or equal to 7mmol
random glucose greater than or equal to 11.1
if asymptomatic above criteria must be met on 2 separate occasions
HbA1C criteria for diagnosing diabetes
if asymptotic- 48 or above
if asymptomatic- need 2 separate readings which are 48 or above
under which conditions would you mot use HbA1C to diagnose diabetes
under 18s
pregnant/2 months postpartum
symptoms for less than 2 months
high diabetes risk who are acutely ill
on medication (long-term corticosteroids) which increase hyperglycaemia risk
acute pancreatic damage (including surgery)
end stage renal disease
HIV
hallmark symptoms of T2D
tiredness
polyuria/polydypsia
recurrent infections (thrush)
increased hunger
unintentional weight loss
blurred vision (retinopathy)
foot ulcers/sores (peripheral neuropathy)
areas of dark skin for example in armpits/neck (acanthuses nigricans)
risk factors for T2D
family history
high BMI
high sugar and fat diet
inactivity
afro-caribbean, hispanic, asian
hyperlipidaemia
over 45
history of gestational diabetes
other conditions which cause insulin resistance- PCOS, haemachromatosis
what do alpha cells in the islets of langerhan produce
glucagon
role of insulin
reduces amount of glucose in blood
binds to its receptors on adipose tissue/muscle
this makes glucose transporter fuse with the cell membrane
glucose is then transported into the cell
role of glucagon
increases the amount of glucose in the blood
stimulates the liver to do gluconeogenesis and glycolysis
is T1D or T2D more common
10%= 1
90%= 2
what type of hypersensitivity is T1D
type 4- T cells attack the pancreas
where genetically is the issue in T1D
on chromosome 6, major histocompatibility complex (MHC), human leukocyte antigen (HLA 3 and 4)
other name of hunger
polyphagia
what causes weight loss and hunger in diabetes
lack of glucose in muscle and adipose tissue
adipose tissue undergoes lipolysis
muscle breaks down into proteins
causes weight loss and hunger
what causes polyuria in diabetes
increased glucose in blood means more filtered by kidneys and more in urine
glucose is osmotically active so draws water with it
what causes polydipsia in diabetes
the excess water loss leads to dehydration and therefore thirst
process of DKA
there is lipolysis of adipose tissue meaning increases fatty acids
the liver converts these to ketone bodies
ketones bodies can be used for energy but they also increase the acidity of the blood- ketoacidosis
what type of respiration may be seen in DKA
kussmaul breathing- this is a deep laboured breathing to reduce CO2 and reduce the acidity of the blood
what electrolyte abnormality may be observed in DKA
hyperkalaemia
what happens to the ions in DKA
there is a high anion gap (large difference in unmeasured ions)
this is due to the ketoacid buildup
what causes fruity breath in DKA
acetone
treatment of DKA
fluids for dehydration
insulin to lower blood glucose
electrolytes (K+)
what happens to the beta cells in T2D
there is hyperplasia and hypertrophy
(this is due to the body producing insulin but there being no response as cells don’t reposed, therefore the body increases beta cells to make more insulin)
amyloid deposits and T2D
the beta cells also make islet amyloid polypeptide (amylin)
hyperplasia and hypertrophy of beta cells mean more amylin- leads to amyloid deposits
the maxed out beta cells can then undergo hypotrophy and hypoplasia
pathophysiology of HHS
when glucose is very high in blood (hyperosmolar state) water goes from the bodies cells meaning they shrivel
blood vessels which are full of water lead to increased urination which leads to total body hydration
overlap between HHS and DKA
in HHS there is sometimes mild ketonemia and acidosis
in DKA there may be some hyperosmolarity
is DKA/HHS more common in type 1 or 2 diabetes
DKA= more common in 1
HHS= more common in 2
what trimester is most commonly affected by gestational diabetes
3rd
what is checked at an annual diabetic review
BP
eye tests
foot examination
blood sugars
urine
HbA1c
height and weight
cholesterol
diet and lifestyle management of T2D
initial weight loss target of 5-10%
reduce alcohol
stop smoking
encourage exercise (150-300mins of moderate intensity aerobic exercise per week)
eat carbohydrates from vegetables, pulses, and whole grains
eat low fat dairy products and oily fat
limit foods with saturated fats/trans fatty acids
when do you give medication for T2D
HbA1C is checked every 3-6months until stable
if lifestyle has failed and is 48 or higher, consider medication
how does metformin work
it is a biguanide
leads to activation of AMP-activated protein kinase (AMPK)
this increases insulin sensitivity and decreases hepatic gluconeogenesis
most common side effect of metformin
GI disturbance (taking with meals/metformin MR can reduce this)
2nd line medication for T2D if metformin isn’t reducing HbA1C
SGLT2 inhibitors (flozin)
when would you consider insulin therapy in T2D
if using 3 medications and HbA1C still not controlled
drugs which reduce insulin resistance in T2D
biguanides (metformin)
thiazolidenediones (pioglitazone)
drugs which increase beta cell activity in T2D
sulphonylureas (gliclazide, glipizide)
meglitinides (nateglinide, repaglinide)
drugs which increase GLP1 activity in T2D
DPP4 inhibitors (sitagliptin, vildagliptin)
incretins, GLP1 agonists (exenatide, liraglutide)
drugs which enhance glucose secretion in T2D
SGLT2 inhibitors (dapaflozin, canagliflozin)
drugs for T2D which can cause weight gain
sulphonyureas
meglitinides
insulin
drugs for T2D which can cause hypoglycaemia
sulphonyureas
meglitinides
insulin
drugs for T2D which can cause GI disturbance
metformin
incretins
acarbose
drugs for T2D which can cause weight loss
metformin
SGLT2 antagonists
incretins
which T2D drug can be associated with osteoporosis
pioglitazone
what other side effect can SGLT2 inhibitors be linked to
UTIs
what hypertension drug class is first line for all diabetes
ACE inhibitors
when would you give statins with diabetes
recommended in most T1D
recommended in T2D if QRISK greater than 10%
what is the blood pressure target for diabetes
below 140/80
below 130/80 if there is end organ damage (kidneys, eyes etc)
diagnostic criteria for DKA
capillary blood glucose over 11 (or known diabetes)
capillary ketones over 3 (or urinary over 2)
venous pH less than 7.3 or venous bicarbonate less than 15
(must have all 3 for diagnosis)
at what rate do you give insulin for DKA
IV fixed rate insulin is at 0.1 units/kg/hr
K+ and insulin
giving insulin drips K+ (makes sense as insulin is used to manage hyperkalaemia)
when would you escalate DKA to critical care
venous bicarbonate less than 5
pH less than 7.1
drowsy GCS of less than 12
stats less than 92% on room air
K+ less than 3.5 on admission
pregnant
HF
oliguria/anuria
persistant hypotension
with DKA when would you change fixed rate IV insulin to subcutaneous insulin
when patient is eating and drinking normally
pH over 7.3 or blood ketones less than 0.6
effect of insulin on adipose tissue and skeletal muscle
increases glucose uptake
increases glycolysis
effect of insulin on liver
increases glycolysis
increases glycogenesis
increases protein synthesis
increases lipogenesis
decreases gluconeogenesis
decreases lipolysis
decreases glycogenolysis
decreases protein breakdown